Pathways to Antimicrobial Clinical Efficacy

Supporting the best innovations to address the global threat of AMR

We can protect more patients worldwide if we tackle the growing threat of antimicrobial resistance. PACE is a £30 million initiative that will focus on early-stage antimicrobial drug and diagnostics projects. It will help our best innovators move their research forward with greater speed and confidence. Through the right funding, partnerships, and expertise, we will give their ideas every chance of succeeding and build a world-leading, pre-clinical AMR pipeline that can save lives.


Managing partners with a vision to connect the AMR community

10 m

Number of estimated deaths from AMR each year by 2050, if no action is taken

£ 30 m

Worth of investment in PACE to tackle AMR

Bringing PACE to AMR research

PACE is a pioneering partnership that will drive the development of new tests and treatments to tackle deadly antimicrobial resistance. It will provide funding and empower scientists and researchers at the early stages of the AMR asset development journey, so they can make a lasting contribution to patient health.

Initiatives aimed at funding and supporting promising research and development to tackle AMR are having significant impact, but we believe PACE will bring a much needed approach and injection of funding and support for a new era of innovation in early-stage translation.

PACE gives us the best chance of making bigger strides towards tackling AMR so we can protect people’s lives across the world. Find out more about PACE.

About PACE

Working with us

If you are an innovator in AMR, then we can increase the pace of your research and make sure it has the best chance of succeeding. PACE will bring together the right funding, resources, and partnerships to help progress early-stage antimicrobial drug and diagnostics projects that address the world’s most threatening pathogens. Learn more about how we can help you.

Apply for Funding

Our Managing Partners

I have always been clear that antimicrobial resistance is one the most severe global health threats that we face globally. Drug-resistant bacterial infections already kill 1.27 million people a year, and experts predict that AMR could kill over 10 million people a year as soon as 2050. I firmly believe that the development of new effective, affordable and equitably accessible antibiotics and rapid diagnostics is not just a medical necessity but a global imperative. I am delighted that through PACE, Medicines Discovery Catapult, Life Arc and Innovate UK will give our science community greater ability to break down the technical, financial and regulatory barriers that have prevented the breakthroughs that our modern medical systems rely on.

Professor Dame Sally Davies

UK Special Envoy on Antimicrobial Resistance